Strategic partnerships eXmoor Pharma shows a strong track record of long-term client relationships with 70% repeat business and recent collaborations with Evox Therapeutics and Siam Bioscience, indicating a receptive environment for expanded collaboration on more complex CGT programs and technology transfer initiatives.

Integrated CDMO advantage As the only integrated UK CGT CDMO with embedded consultancy across strategy, development, and GMP manufacturing, eXmoor offers a compelling one-stop solution for clients seeking end-to-end support, enabling sales teams to target biotech startups and mid-stage biopharmas aiming to accelerate timelines.

Leadership expansion Recent leadership appointments including a new Chair, Chief Commercial Officer, and Chief Operating Officer signal a strategic push to scale operations, customer engagement, and go-to-market capabilities, presenting opportunities to discuss capacity, throughput, and program leadership reliability.

Modality and tech breadth Capabilities span Viral Vectors, autologous and allogeneic cell therapies, and RNA technologies with a focus on process development and GMP manufacturing, suggesting cross-sell potential into multiple CGT modalities for existing and prospective clients pursuing diverse therapy platforms.

Global reach and funding With a substantial project portfolio from academic to global pharma clients, a funding base of about $35M, and a revenue footprint in the $1M–$10M range, there is opportunity to position eXmoor as a scalable partner for growth-stage companies needing risk-managed scale-up and international GMP readiness.